OBJECTIVES : This study investigated key predictors that impacted QoL for patients with FL across EU5.

METHODS : Real world data were drawn from the FL Disease-specific Programme^TM - a point in time study administered to haem-oncologists who completed patient record forms for the next 8 consulting patients with FL in Q2/3 2017 across EU5. QoL analysis was conducted on those that completed a patient self-completion form (PSC). Statistical methods used included Spearman’s rank correlation coefficient, bivariate analysis, and multiple linear regression.

RESULTS : Data analysis was conducted on 1,534 patients diagnosed with FL, of whom 591 completed a PSC. Patients that completed a PSC were more likely to be at 1^st line (31% vs 23%; p=0.0035), responding to treatment at time of study (21% vs 16%; p=0.0061) and experience fewer comorbidities (1.2 vs 1.3; p=0.0169) than those that didn’t complete a PSC.

Characteristics of patients that completed a PSC were: mean age 65.1 years (SD=11.3), patients were most commonly grade 2 and stage III (43%; 41%), on their 2^nd line of therapy (59%) and had an ECOG of 1 (53%).

Multiple QoL measures (FACT and WPAI), ECOG score and presence of comorbidities were significantly correlated with the EQ5D-5L (p<0.05). Comorbidities and ECOG score were key predictors of the EQ5D-5L. Patients on later lines of therapy had worse QoL (line 1-line 3; p-value), including EQ5D-5L (0.82-0.59; p<0.0001), FACT-G score (67.79-54.87; p<0.0001), and FACT-Lymphoma score (109.29-87.94; p<0.0001). With increasing lines of therapy, patients receiving induction therapy had better QoL compared to those on maintenance therapy (EQ5D-5L: 0.81-0.77; p=0.5739 vs 0.86-0.23; p<0.0001, FACT-G score: 66.42-63.34; p=0.2136 vs 72.05-38.77; p<0.0001, FACT-Lymphoma score: 106.86-104.11; 0.3822 vs 116.80-57.23; p<0.0001).

CONCLUSIONS : Patients on later lines of therapy and maintenance therapy, show a deterioration of their QoL, highlighting the need for novel treatment options to maintain QoL in these settings.